ArticleEuropean journal of case reports in internal medicine2023
Recurrent High-Risk Pulmonary Thromboembolism Treated with Repeated Thrombolytic Therapy Could be Helpful for Certain Patients: A Case Report and Review of the Literature.
Article in European journal of case reports in internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- Efficacy and safety of low-dose thrombolysis in intermediate-risk pulmonary embolism: a meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Re-administration of thrombolytics in massive pulmonary embolism with initial therapy failure: a case report.Thrombosis journal · 2026Article
- Article
- Safety and efficacy of low-dose versus high-dose alteplase for pulmonary embolism: a retrospective study from MIMIC-IV.Journal of thoracic disease · 2026Article
- Sequential Systemic Thrombolysis for Clot-In-Transit after Thrombolytic Failure in Massive Pulmonary Embolism.European journal of case reports in internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pulmonary thromboembolism (PTE) is considered the third most frequent acute cardiovascular syndrome behind myocardial infarction and stroke, with annual incidence rates ranging from 39 to 115 per 100,000 people and ranking high among the causes of cardiovascular mortality. High-risk PTE is characterised by haemodynamic instability and encompasses clinical manifestations such as cardiac arrest, obstructive shock and persistent hypotension. The European Society of Cardiology (ESC) recommends a reperfusion strategy with systemic thrombolytic therapy for high-risk PTE under class I, level B if there are no contraindications. Overall, unsuccessful thrombolytic therapy and recurrent PTE have been reported in 8% of patients with high-risk PTE. The guidelines recommend surgical pulmonary embolectomy if thrombolysis is contraindicated or has failed. The position of repeated thrombolytic therapy as a treatment option in patients with recurrent high-risk PTE, especially in situations with a lack of surgical expertise or resources, was not mentioned in the guidelines. We report the case of a patient who suffered a recurrent high-risk PTE and was treated with repeated thrombolytic therapy that was effective and resulted in excellent outcomes. LEARNING POINTS: Acute pulmonary thromboembolism (PTE) is a serious medical condition and widespread disease with well-recognised morbidity and mortality.Systemic thrombolytic therapy should be the first choice in patients with high-risk PTE without contraindication.Repeated thrombolytic therapy in recurrent high-risk PTE might be effective in patients with low risk of bleeding as an alternative to surgical embolectomy or catheter-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.